Prognostic value of myeloperoxidase in patients with chest pain.
By M. Brennan, M. Penn, F. van Lente, Vijay Nambi, M. Shishehbor, Ronnier J. Aviles, M. Goormastic, M. Pepoy, E. McErlean, Eric J. Topol and 2 more. New England Journal of Medicine, 2003
1,125 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Immunology
View Paper: https://www.semanticscholar.org/paper/2c23c4fea53b47a934db61d02370cfc17b6c5aa9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Myeloperoxidase: friend and foe (2005, background): “Further, increased plasma [476] or serum [477] MPO levels in patients with coronary artery disease may serve to identify patients with an increased risk for further cardiovascular events (see ref.”
- Biological markers of oxidative stress: Applications to cardiovascular research and practice (2013, background): “…studies, high MPO levels were able to predict increased risk of developing CAD in healthy individuals [74]; cardiovascular events in patients presenting to emergency with chest pain [75]; and increased risk of myocardial infarction and death in patients with acute coronary syndrome [76].”
- Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. (2004, background): “Plasma, serum, and leukocyte MPO levels have now been associated with angiographic evidence of coronary artery disease (32); incident risk of myocardial infarction, death, and need for revascularization (33, 34); and enhanced endothelial dysfunction (83).”
- Role of oxidative modifications in atherosclerosis. (2004, background): “peroxidase (91) are associated with increased risk of events.”